Using Mirabegron to Increase Blood Pressure in Patients With Postural Orthostatic Tachycardia Syndrome
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately responsive to conventional treatments. The American Heart Association funds this study.
• Provision of signed and dated informed consent form.
• Age \> 18 years old.
• Documented history of chronic (\> 3 months) of orthostatic intolerance.
• Diagnosis of syncope or pre-syncope and documented intermittent hypotension unresponsive to conventional life-style modification therapy.
‣ A history of syncope (complete loss of consciousness) or presyncope (the sensation that one is about to pass out).
⁃ At least one documented hypotensive episode with systolic BP \< 90 mmHg on 24-hr ABPM.
⁃ Inadequate response to conventional therapies.